TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04743544

Intervention type: DRUG
Intervention: Voriconazole
Description: This is an observational study and only the patients already on voriconazole treatment will be included in the study.
Study: NCT01026519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN88
Description: Single dose of REGN88 and 43 day follow up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN88
Description: Single dose of REGN88 and 43 day follow up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN88
Description: Single dose of REGN88 and 43 day follow up.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match REGN88 administration
Study: NCT02648139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dentifrice
Description: 3x/day for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dentifrice
Description: 3x/day for 7 days.
Study: NCT01478412

Intervention type: OTHER
Intervention: Polymer based fiducial placement
Description: Fiducial marker placement with rectal ultrasound imaging.
Study: NCT02836002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (low dose)
Description: - subcurative regimen (500mg/25mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (low dose)
Description: - subcurative regimen (500mg/25mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine (low dose)
Description: - subcurative regimen (480 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine (low dose)
Description: - subcurative regimen (480 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (high dose)
Description: - curative regimen (1000mg/50mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (high dose)
Description: - curative regimen (1000mg/50mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine (high dose)
Description: - curative regimen (960 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine (high dose)
Description: - curative regimen (960 mg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: malaria challenge infection, P. falciparum 3D7
Description: malaria challenge infection by P. falciparum 3D7-infected mosquito bites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: malaria challenge infection, P. falciparum 3D7
Description: malaria challenge infection by P. falciparum 3D7-infected mosquito bites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: malaria challenge infection, P. falciparum 3D7
Description: malaria challenge infection by P. falciparum 3D7-infected mosquito bites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: malaria challenge infection, P. falciparum 3D7
Description: malaria challenge infection by P. falciparum 3D7-infected mosquito bites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil
Description: - curative regimen: 1000/400 mg, for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil
Description: - curative regimen: 1000/400 mg, for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil
Description: - curative regimen: 1000/400 mg, for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil
Description: - curative regimen: 1000/400 mg, for 3 days
Study: NCT01724697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMSC transplantation
Description: Patients randomized to the intervention arm will be collected for bone marrow stem cells and then infused with these cells via hepatic artery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment & antivrial treatment
Description: Participants will recieve conventional treatment and antivrial treatment.
Study: NCT01714830

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: standars electromagnetic DUOLITH SD1
Description: In the first group patients will be treated by ESWT once a week for 4 weeks. (Each time 3000 impulses, with 0.25 mJouls/M2 and 3 Hertz of frequency. After each 500 pulses, the probe position will be corrected, using trans-perineal ultrasound.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: turn off standars electromagnetic DUOLITH SD1
Description: In the control group, the same protocol is applied but with the probe being turned off.
Study: NCT01858844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHEST COMPRESSION TECHNIQUE (CCT)
Description: The CCT was held with the placement of one of the hands were not engaged in. The following has been applied a symmetric oblique direction, pressure from top to bottom on the half thorax rib cage so that it went according to the complacency of the ribcage. This pressure was applied in the expiratory phase and held for 10 seconds, totaling 6 repetitions of the maneuver during 60 seconds. The other hand held on the contralateral iliac crest to stabilize the patient. The technique was held during 5 consecutive minutes with range of a respiratory incursion every 60 seconds. Immediately after and 10 minutes after the end of the application of the technique, the data was measured again.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHEST COMPRESSION TECHNIQUE (CCT)
Description: The CCT was held with the placement of one of the hands were not engaged in. The following has been applied a symmetric oblique direction, pressure from top to bottom on the half thorax rib cage so that it went according to the complacency of the ribcage. This pressure was applied in the expiratory phase and held for 10 seconds, totaling 6 repetitions of the maneuver during 60 seconds. The other hand held on the contralateral iliac crest to stabilize the patient. The technique was held during 5 consecutive minutes with range of a respiratory incursion every 60 seconds. Immediately after and 10 minutes after the end of the application of the technique, the data was measured again.
Study: NCT04321629

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: autologous adipose tissue transfer
Description: experimental group: liposuction, adipose tissue preparation and intra-articular injection

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PRP injections
Description: control group: blood collection, blood preparation and intra-articular PRP injection
Study: NCT01236508

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT imaging with F-18 fluorodeoxyglucose
Description: Dose of 5 MBq/kg F-18-FDG given to fasting participant. Nuclear whole body imaging starting at 3 hours post-injection. The relation of the PET/CT image results and both the number of covert brain infarcts and the extent of white matter MRI hyperintensity will be investigated.
Study: NCT03761602

Intervention type: OTHER
Intervention: Not applicable (for observational studies)
Description: This study is an observational study. No intervention will be administered for research purposes.

Intervention type: OTHER
Intervention: Not applicable (for observational studies)
Description: This study is an observational study. No intervention will be administered for research purposes.

Intervention type: OTHER
Intervention: Not applicable (for observational studies)
Description: This study is an observational study. No intervention will be administered for research purposes.
Study: NCT03227081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Description: Sleep Deprivation
Study: NCT04545671

Intervention type: OTHER
Intervention: trifocal lens
Description: not applicable as patients are already implanted with the trifocal lens
Study: NCT00640120

Intervention type: DEVICE
Intervention: WIM-PC™ device
Description: wheeze detection during dynamic bronchial situations in infants
Study: NCT00990652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Before surgery, an injection of bortezomib is given on days 1, 4, and 8. After surgery, bortezomib is given on days 7 and 21 of each cycle (1 cycle = 28 days).
Study: NCT00734994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperthermia System
Description: Hyperthermia applied to heat the bladder to a temperature of 42 degrees Celsius for 40-60 minutes concurrent with mitomycin Treatment Schedule: 6 Weekly Sessions (Induction) followed by 4 Monthly Sessions (Maintenance) until documented second recurrence

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: 40 mg in 40 ml sterile water instilled into bladder
Study: NCT03491293

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss + Text
Description: Participants will attend weekly one hour classes on line. They will type their input and responses within the chat room. They will record their calorie and fat intake daily and weigh themselves daily. Interventionists will review the diaries weekly and provide feedback to reinforce or shape new behaviors and to identify high risk situations for problem solving.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss + Video
Description: Participants will attend weekly one hour classes on line. They will have audio and video within the chat room, and will talk with their facilitator and classmates during their weekly meeting. They will record their calorie and fat intake daily and weigh themselves daily. Interventionists will review the diaries weekly and provide
Study: NCT01660633

Intervention type: DRUG
Group type: OTHER
Intervention: High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)
Description: 200 mg melphalan/m2 will be divided into two separate, consecutive doses of 100 mg/m2 administered on day -3 and day -2 prior to ASCT. The High-Dose Melphaln HCL for Injection (Propylene Glycol-Free) will be reconstituted to 5 mg/mL (also containing 270 mg/mL of Captisol®). The Melphalan HCL for Injection (Propylene Glycol Free) will be further diluted with normal saline to a concentration of no greater than 0.45 mg/mL and infused over 30 minutes ( + or - 3 minutes)via a central venous catheter.

Intervention type: OTHER
Group type: OTHER
Intervention: Autologous Transplantation
Description: Patients who are myeloablative conditioning in multiple myeloma undergoing autologous transplantation( patients own blood-forming stem cells are collected to replace diseased bone marrow or bone marrow damaged by cancer treatment)
Study: NCT00854620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib administered in escalating 28-days cycles (400, 600 and 800 mg BID)
Study: NCT01608633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spray and stretch
Description: Physiotherapeutic technique which consist in stretching the muscle while a cold spray is applied on the skin.
Study: NCT03947788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OKQ Training Program
Description: The OKQ training program helps clinicians more efficiently meet the needs of women's pregnancy intentions and provide evidence-based care.
Study: NCT02717286

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: restorative
Description: It was performed direct restoration using two kinds of adhesive system (total-etching adhesive and self-etching adhesive)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: restorative
Description: It was performed direct restoration using two kinds of adhesive system (total-etching adhesive and self-etching adhesive)
Study: NCT01063725

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Femarelle
Description: A soy based food supplement containing 322 mg of soy extract and 108 mg of flaxseed, to be taken twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing 430 mg of microcrystalline cellulose, as a placebo, to be taken twice daily
Study: NCT03953781

Intervention type: DRUG
Intervention: Effect of valporate on Reproductive Functions in Newly Diagnosed Epileptic Males
Study: NCT00990652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: After surgery, temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle (1 cycle = 28 days).
Study: NCT01821664

Intervention type: DEVICE
Intervention: Prosthetic vascular graft
Description: Implantation of a prosthetic vascular graft
Study: NCT01310036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg was administered orally daily until disease progression or unacceptable toxicity.
Study: NCT02938000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theraband with exercise video
Description: Theraband exercise band for resistance training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual care with advice to exercise
Description: advice to exercise
Study: NCT01175668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: This group of infants undergoing NAS will be treated with neonatal morphine sulfate and Clonidine as an adjunct medication to control the symptoms. Once stable Finnegan scores \<8 for 24h, NMS will be weaned by 10% daily till off, then Clonidine will be weaned off in a stepwise manner. Infant will not go home on any medication for NAS. NMS will be dosed as mg/kd/day divided q3h and Clonidine will be dosed as microgm/kg/day divided q6h based upon the initial Finnegan scores.
Study: NCT03953781

Intervention type: DRUG
Intervention: Effect of levetiracetam on epileptic males reproductive function
Study: NCT00571922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acamprosate
Description: 2 gr/day (333 mg, TID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study: NCT04733235

Intervention type: DRUG
Intervention: Progesterone
Description: ultrasound measurements of endometrial thickness at the end of the estrogen phase and the day of embryo transfer.

Intervention type: DRUG
Intervention: Progesterone
Description: ultrasound measurements of endometrial thickness at the end of the estrogen phase and the day of embryo transfer.
Study: NCT03368495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Co-administration of MMR/YF
Description: Both MMR \& yellow fever vaccines administered on Day 0.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR followed by YF
Description: MMR vaccine administered on Day 0 and yellow fever vaccine administered on Day 28.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: YF followed by MMR
Description: Yellow fever vaccine administered on Day 0 and MMR vaccine administered on Day 28.
Study: NCT01149616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 8mg iv x1
Description: Dexamethasone 8mg iv x1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 ml normal saline IV x1
Study: NCT01110499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210961 Formulation 1
Description: AGN-210961 Formulation 1 in one eye once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210961 Formulation 2
Description: AGN-210961 Formulation 2 in one eye once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210961 Formulation 3
Description: AGN-210961 Formulation 3 in one eye once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210961 Formulation 4
Description: AGN-210961 Formulation 4 in one eye once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210961 Formulation 5
Description: AGN-210961 Formulation 5 in one eye once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210961 Formulation 6
Description: AGN-210961 Formulation 6 in one eye once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210961 Formulation 7
Description: AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost ophthalmic solution 0.03%
Description: bimatoprost ophthalmic solution 0.03% (LUMIGAN®) in both eyes once daily for 4 weeks.
Study: NCT02301962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab is available as a concentrate for solution for infusion (sterile concentrate). It is a colorless solution that may contain, translucent to white, visible amorphous, proteinaceous panitumumab particles. Each milliliter (mL) of concentrate contains 20 mg panitumumab. Each vial contains 100 mg of panitumumab in 5 mL.
Study: NCT02513459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab 600 mg IV
Description: Re-induction treatment; 3 infusions every 4 weeks, after which eligibility was assessed if clinical response was re-gained

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab 180 mg SC
Description: Maintenance treatment every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
Study: NCT03145883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-Based Aerobic Exercise
Study: NCT01175668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital
Description: Infants in this arm will be treated as current standard practice with NMS and Phenobarbital. NMS will be weaned by 10% daily to completely off during the hospital stay. Infants will be discharged home on Phenobarbital.~NMS will be dosed as mg/kg/day divided q3h and Phenobarbital will be dosed as mg/kg/day divided q8h based on the Finnegan scores.
Study: NCT02519972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low dose computed tomography
Description: Participants will receive 3 round of low dose computed tomography screening every year
Study: NCT01732965

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phototherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phototherapy and Photochemotherapy
Study: NCT04725526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile phone compatible with iOS or Android
Description: MHealth (mobile health) intervention is an act whose purpose is to improve, maintain, promote or modify health, functioning or health conditions.
Study: NCT00455533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Intravenous Solution, intravenous (IV), 40mg/m², Day 1 every 21 days, 12 Weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Intravenous Solution, IV, 80mg/m², Weekly, 12 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous Solution, IV, 600mg/m², Day 1 every 21 days, 12 Weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Intravenous Solution, IV, 600mg/m², Day 1 every 21 days, 12 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Intravenous Solution, IV, 60mg/m², Day 1 every 21 days, 12 Weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Intravenous Solution, IV, 60mg/m², Day 1 every 21 days, 12 Weeks
Study: NCT02904200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicon adhesive dressing
Description: Sterile soft silicon adhesive dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acrylic adhesive dressing
Description: Sterile acrylic adhesive dressing
Study: NCT02749019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-BBN-RGD
Description: 68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
Study: NCT02817854

Intervention type: PROCEDURE
Intervention: Measure PCT, CRP and WBC at admission
Description: Measure PCT, CRP and WBC at admission after diagnosis of acute diverticulitis with CT scan has been done

Intervention type: PROCEDURE
Intervention: Measure PCT, CRP and WBC 1 day after admission
Description: Measure PCT, CRP and WBC at one day after admission for acute diverticulitis

Intervention type: PROCEDURE
Intervention: Measure PCT, CRP and WBC 2 days after admission
Description: Measure PCT, CRP and WBC at 2 days after admission for acute diverticulitis
Study: NCT01042496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: 12 week open trial: 25mg/day for 2 weeks, 50mg/day for 2 weeks, 100mg/day for 2 weeks, 200mg/day for 6 weeks. Flexible titration for early response and/or side effects.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1H-MR
Description: Proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1H-MR
Description: Proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC).
Study: NCT00772252

Intervention type: OTHER
Intervention: liver support treatment
Description: plasma exchange for liver support treatment
Study: NCT04426526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL 799-2
Description: High power magnet system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL 799-2
Description: High power magnet system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL 799-2
Description: High power magnet system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL 799-2
Description: High power magnet system
Study: NCT00436878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food portion size
Description: Each of four experiments involves a 2 x 2 within-subjects factorial design, in which the first factor is the portion size of a food served to children: foods will be served in a reference amount (i.e. 250 g macaroni and cheese) or doubled in size(i.e. 500 g of macaroni and cheese). In the Experiment 1, the second factor of the 2 x 2 design is meal type: whether the food is consumed at a meal or a snack. In experiment #2, the second factor is food type: fruit vs. vegetable. In experiment #3, the second factor is entree energy density: a regular energy density or a 40% greater energy density. In experiment #4, the second factor is plate size: a 6 inch plate vs. a 10 inch plate.
Study: NCT01484665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROCASE Decision-Aid
Description: VA health services researchers have developed a patient education pamphlet for prostate cancer screening. The pamphlet, titled The PSA test for prostate cancer: Is it Right for ME was created by members of the PROstate CAncer Screening Education (PROCASE) study team. A modified version of the PROCASE decision aid will be utilized in this study.